SCHEMBL6029601

SCHEMBL6029601

COC(=O)C(Cc1ccccc1)NC(=O)c1ccc(Cl)nc1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 2/20 0.64
GAA P10253 1/20 0.64
LMNA P02545 2/20 0.61
GABRA5 P31644 1/20 0.57
L3MBTL1 Q9Y468 1/20 0.56
NPC1 O15118 1/20 0.54
SMN1; SMN2 Q16637 1/20 0.54
ALDH1A1 P00352 3/20 0.54
GLA P06280 1/20 0.54
CTSL P07711 2/20 0.53
HPGDS O60760 3/20 0.53
ATM Q13315 1/20 0.52
THRB P10828 1/20 0.51
CYP2C9 P11712 1/20 0.51
CYP2C19 P33261 1/20 0.51
HSD17B10 Q99714 1/20 0.51
PYGL P06737 1/20 0.51
TACR3 P29371 1/20 0.50
CTSS P25774 1/20 0.50
POLB P06746 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28603072 0.84 GAA (0.71) RAB9AGAALMNAALDH1A1GLA
SCHEMBL16495994 0.83 GAA (0.55) RAB9AGAAGABRA5HPGDSPYGL
SCHEMBL16495995 0.83 GAA (0.55) RAB9AGAAGABRA5HPGDSPYGL
SCHEMBL31206887 0.82 GAA (0.76) RAB9AGAALMNAL3MBTL1ALDH1A1
SCHEMBL1793176 0.82 GAA (0.76) RAB9AGAALMNAL3MBTL1ALDH1A1
SCHEMBL2461492 0.82 GAA (0.76) RAB9AGAALMNAL3MBTL1ALDH1A1
SCHEMBL13525006 0.81 GAA (0.70) RAB9AGAALMNAL3MBTL1ALDH1A1
SCHEMBL6860349 0.81 ECE1 (0.62) RAB9AGAALMNANPC1SMN1; SMN2
SCHEMBL26814850 0.80 RAB9A (0.70) RAB9AGAALMNANPC1SMN1; SMN2
SCHEMBL4175147 0.80 GAA (0.73) RAB9AGAALMNAL3MBTL1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060247260-A1 Bis (hetero) aryl carboxamide derivatives for use as PG12 antagonists BAYER HEALTHCARE AG (DE) 2006-11-02 US disclosed
EP-1594846-A1 BIS(HETERO)ARYL CARBOXAMIDE DERIVATIVES FOR USE AS PGI2 ANTAGONISTS Bayer HealthCare AG (DE) 2005-11-16 EP disclosed
WO-2004069805-A1 BIS(HETERO)ARYL CARBOXAMIDE DERIVATIVES FOR USE AS PGI2 ANTAGONISTS BAYER HEALTHCARE AG (DE) 2004-08-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060247260-A1 Bis (hetero) aryl carboxamide derivatives for use as PG12 antagonists HRH2, BPHL, HRH1 RAB9A 3403/4885GAA 3163/4885LMNA 2162/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.